leisure time -WSS

leisure time

author：knowledge 2025-10-01 10:59:23 - browse：59

Why are addiction treatments so hard to get? Can small companies compete in obesity? And since when is “Series E” a thing in biotech?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. For the entirety of the opioid overdose epidemic, the U.S. has had readily available tools that are proven to save lives. STAT’s Lev Facher joins us to explain his reporting on why virtually every sector of American society is standing in the way of their use. We also discuss the latest news in the life sciences, including the haves and have-nots of venture capital, and the race to develop effective oral treatments for obesity.

For more on what we cover, here’s the story on addiction medicine; here’s the latest on biotech financing; here’s more on Novo Nordisk’s oral obesity treatment; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： How one medical school became remarkably diverse
Next article： Winning ticket for $1 billion Powerball jackpot sold in California

WSS

EF3 tornado rips through North Carolina amid extreme weather nationwide

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Readout Newsletter: Bayer's future, Merck Caraway acquisition, etc

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Senate committee advances SCOTUS ethics bill after alleged justice misconduct

Wikipedia

leisure time

focus

Drug repurposing or repositioning? The language matters

Gain of function research would be limited under House proposal

In age of alternative facts, a scholarly course on calling out crap

Readout Newsletter: What is Casgevy? Does Wegovy hurt muscle?

Wildfire smoke exposes gaps in outdoor worker protections

Stanford president's case begs question: Who takes blame?

Cancer drug shortages should be causing more outrage

Gain of function research would be limited under House proposal

Continuity nursing helped my family in our darkest PICU moments

Tocagen's brain cancer gene therapy trial continues. Investors worry

explore

Morphosys mixed study results for blood cancer drug

Anthos stroke drug appears safer than common blood thinner

Tocagen's brain cancer gene therapy trial continues. Investors worry

Poor hospice wound care hurts patients and families

Anthos stroke drug appears safer than common blood thinner

Tocagen's brain cancer gene therapy trial continues. Investors worry

Wikipedia

hotspot

hotspot

focus